AKUR8
27.7.2021 09:02:06 CEST | Business Wire | Press release
Akur8 is pleased to announce its collaboration with Beesafe and Compensa, two entities of VIG Poland, to enhance their pricing process. With this new milestone, Akur8 continues to expand its European footprint, with 7 countries to date.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005010/en/
Specifically developed for insurers, Akur8’s solution boosts their pricing processes by automating risk and demand modeling, using transparent Artificial Intelligence proprietary technology. The core benefit for insurers is greater speed-to-accuracy, while maintaining full transparency and control on the models created.
VIG (Vienna Insurance Group) is one of the largest insurance groups in the world and one of the leading insurers in Austria and CEE countries. By collaborating with Akur8 for their motor insurance lines, Compensa will further accelerate their digital transformation, transforming the very core pricing process. Beesafe, a new, fully digital and direct entity created by VIG Poland, will be using Akur8 to launch their new product, leveraging the accelerated time-to-market benefits.
“We are very happy to support Beesafe and Compensa, part of VIG Poland, in taking a critical step towards insurance pricing sophistication and spurring digital transformation in their field. We are particularly humbled to accompany Beesafe in the launch of their fully digital journey, to help them bring their product to Polish consumers in a timely manner.”, says Samuel Falmagne, CEO at Akur8.
“It is great to be able to support VIG Poland in the launch of a new venture, whilst also reinforcing Akur8’s presence in Europe, Poland being our seventh European country of presence to date.”, says Brune de Linares, Chief of Sales at Akur8.
“Beesafe is a purely digital venture with a strong insurtech identity that we are extremely proud to be launching despite a very challenging context undermined by Covid. This is a strong testimony to the team’s commitment to continue to fuel digital transformation in our sector, sustained by collaborations with top-notch solutions that Akur8 epitomizes, for a highly strategic process that is pricing, all the more when launching a new product.”, says Rafał Mosionek, CEO at Beesafe and Executive Committee Member at Compensa, VIG Poland.
About Akur8
Akur8
is revolutionizing insurance pricing with transparent AI. Akur8 developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control on the models created, as required by regulators worldwide. Akur8 is the only solution on the market reconciling Machine Learning and Actuarial worlds.
About Beesafe
Beesafe
is a digital venture with a strong insurtech identity, benefiting from a quite unique positioning within the CEE area. The digital start-up was established by VIG, the leading insurance group in Austria, Central and Eastern Europe, to provide a dynamic distribution company with a unique customer offering, and potential for expansion into other countries where VIG operates.
About Compensa
Part of the Vienna Insurance Group, Compensa has been operating on the Polish market for many years, constantly developing its offer, service standards and sales network to exceed the expectations of the growing number of customers.
About VIG
Vienna Insurance Group (VIG)
is a leading specialist insurance company in Austria and Central and Eastern Europe. About 50 companies in 30 countries belong to it. It is a company with a long tradition, having strong brands and attaching great importance to customer proximity. VIG bases its activity on the foundation of almost 200 years of experience in the insurance industry. The Vienna Insurance Group, with around 25,000 employees, is the undisputed leader in the group's key markets and thus has an excellent market position enabling it to take advantage of long-term growth opportunities in a region with 180 million people.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005010/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom